Urine and MRI approach to find aggressive prostate cancer early
Official title: UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)
Run by University of Michigan Rogel Cancer Center · NCT07526545 · Data updated 2026-11-12
This study tests whether a urine test called MPS2, paired with MRI, can better detect aggressive prostate cancer in men 50–75 at risk, possibly reducing unnecessary biopsies.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 75 Years |
| Sex | Men only |
| Enrollment | 800 (estimated) |
| Sponsor | University of Michigan Rogel Cancer Center Academic / other |
| Locations | 1 site (Ann Arbor, Michigan) |
| Status | Recruiting |
| Started | December 1, 2026 |
| Main results expected | June 1, 2030 |
| Study ends | June 1, 2030 |
| Registry record updated | October 15, 2026 |
| Trial ID | NCT07526545 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men aged 50–75 with PSA 3–20 ng/ml who have not recently had a biopsy or MRI and are medically able to undergo MRI and biopsy.
✕Probably not a fit
Patients with cancers not detectable by MPS2 or MRI, or those who do not have aggressive disease, may see limited benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial evaluates the combination of a urine-based biomarker test (MPS2) with MRI to improve early detection of clinically significant prostate cancer. Enrollment targets men aged 50–75 with PSA 3–20 ng/ml who are deemed fit for the procedures and have not had a biopsy in 4 years or an MRI in 2 years. Participants will undergo biopsy as part of the diagnostic workup, along with MRI and review of electronic health records to correlate results. The study aims to determine if this integrated approach can better identify cancers that require treatment while avoiding over-diagnosis. Findings could shift current screening practices and reduce unnecessary imaging and invasive procedures if successful.
Why it matters
Potential benefit: If successful, participants may benefit from more accurate early detection and a lower chance of unnecessary biopsies.
How similar studies have gone: Previous work in combining urine biomarkers with imaging has shown promise, but this specific integrated MPS2+MRI approach is novel or has limited published results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males aged 50-75 * PSA 3-20 ng/ml within the previous 3 months * Fit to undergo all procedures listed in protocol per treating physician's discretion * No prostate biopsy in the past 4 years * No prostate MRI in the past 2 years * Able to provide written informed consent Exclusion Criteria: * Prior diagnosis of prostate cancer * Contraindication to MRI (e.g. claustrophobia, pacemaker) * Contraindication to prostate biopsy * Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work
Where it's running
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States Recruiting
Study contacts
- Principal investigator: Udit Singhal, MD — University of Michigan Rogel Cancer Center
- Study coordinator: Uprise StudyTeam
- Email: uprise-spore@med.umich.edu
- Phone: 734-615-6662
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding NK Cell Function in Prostate Cancer Across Races
This study tests whether natural killer (NK) cells behave differently in prostate cancer patients of diverse racial backgrounds by analyzing blood and tissue samples.
-
MRI or CT planning to guide high-dose-rate prostate brachytherapy
This trial tests whether adding an MRI to CT-based treatment planning for HDR prostate brachytherapy changes urinary side effects in men with localized prostate cancer.
-
Targeted Early Detection for Men at High Genetic Risk for Prostate Cancer
This study tests urinary biomarkers and PSA to see if they can improve early detection for men with a strong family or genetic risk for prostate cancer.
-
GET FIT Together: a socially enhanced exercise program for older men with prostate cancer
This program tests whether adding structured social support to supervised online exercise reduces cancer-related loneliness and improves mental and physical health in men 65 and older who have had prostate cancer.
-
Improved MRI methods to distinguish benign from cancerous pelvic findings
This test tries new deep-learning image-processing methods on MRI scans to get clearer images faster for adults scanned for prostate screening or suspected endometriosis.
-
Decision support to help germline genetic testing for men with prostate cancer
A tool is being tested to help men with prostate cancer decide about germline genetic testing and see if it increases testing completion.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.